Skip to content
Triangle logo TriangleGet started
← Full study record

NCT02883049 · OUTCOME

Overall Survival (OS) Rate for HR B-ALL Patients, Overall and by Randomized Arm

Combination Chemotherapy in Treating Young Patients With Newly Diagnosed High-Risk B Acute Lymphoblastic Leukemia and Ph-Like TKI Sensitive Mutations · Source last updated 2026-06-02

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure
NUMBER
Unit
Percentage of patients
Interval / dispersion
95% Confidence Interval
Time frame
At 5 years

What was measured

OS time is defined as time from enrollment to death or date of last contact for patients who are alive. 5-year OS will be estimated for the two randomized arms using the Kaplan-Meier method.

Analysis population: Total HR B-ALL patients (includes patients from AALL0932). Inevaluable and ineligible patients were excluded from analysis.

Groups in this outcome

Non-DS HR B-ALL Overall

Total Non-DS HR B-ALL patients

Non-DS HR B-ALL Arm A

Non-DS HR patients receive post induction age-adjusted intrathecal (IT) methotrexate (MTX)

Non-DS HR B-ALL Arm B

Non-DS HR patients receive post-Induction age-adjusted intrathecal triple therapy (ITT) on a Modified Berlin-Frankfurt-Munster (MBFM) interim maintenance high-dose methotrexate (IMHDM) backbone

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

GroupSource count
Non-DS HR B-ALL Overall1734
Non-DS HR B-ALL Arm A868
Non-DS HR B-ALL Arm B866

Reported measurements

Source class 1
Values in Percentage of patients · Interval/dispersion: 95% Confidence Interval
GroupValueSpreadLowerUpperComment
Non-DS HR B-ALL Overall96.65Not reported95.897.5Not reported
Non-DS HR B-ALL Arm A97.05Not reported95.998.2Not reported
Non-DS HR B-ALL Arm B96.25Not reported94.997.6Not reported
Complete source fields
classes
  1. categories
    1. measurements
      1. group Id
        OG000
        lower Limit
        95.8
        upper Limit
        97.5
        value
        96.65
      2. group Id
        OG001
        lower Limit
        95.9
        upper Limit
        98.2
        value
        97.05
      3. group Id
        OG002
        lower Limit
        94.9
        upper Limit
        97.6
        value
        96.25
denoms
  1. counts
    1. group Id
      OG000
      value
      1734
    2. group Id
      OG001
      value
      868
    3. group Id
      OG002
      value
      866
    units
    Participants
description
OS time is defined as time from enrollment to death or date of last contact for patients who are alive. 5-year OS will be estimated for the two randomized arms using the Kaplan-Meier method.
dispersion Type
95% Confidence Interval
groups
  1. description
    Total Non-DS HR B-ALL patients
    id
    OG000
    title
    Non-DS HR B-ALL Overall
  2. description
    Non-DS HR patients receive post induction age-adjusted intrathecal (IT) methotrexate (MTX)
    id
    OG001
    title
    Non-DS HR B-ALL Arm A
  3. description
    Non-DS HR patients receive post-Induction age-adjusted intrathecal triple therapy (ITT) on a Modified Berlin-Frankfurt-Munster (MBFM) interim maintenance high-dose methotrexate (IMHDM) backbone
    id
    OG002
    title
    Non-DS HR B-ALL Arm B
param Type
NUMBER
population Description
Total HR B-ALL patients (includes patients from AALL0932). Inevaluable and ineligible patients were excluded from analysis.
reporting Status
POSTED
time Frame
At 5 years
title
Overall Survival (OS) Rate for HR B-ALL Patients, Overall and by Randomized Arm
type
SECONDARY
unit Of Measure
Percentage of patients

Download exact source JSON → · Snapshot ctgov-results-191f4516d4760045304b24a0

Preserved source evidence · Not medical advice